Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data
Recruiting
Observational Study
Non-small Cell Lung Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 144,400 (estimated)
- Sponsor
- University of Utah · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This research will leverage machine learning (ML) and causal inference techniques applied to real-world data (RWD) to generate evidence that personalizes treatment strategies for patients with advanced non-small cell lung cancer (aNSCLC). Rather than influencing regulatory decisions or clinical guidelines, the goal of this trial is to refine treatment selection among existing therapeutic options, …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
Subjects must meet all of the following eligibility criteria:
* Diagnosed with advanced NSCLC between January 1, 2011, and June 30, 2024.
* Follow-up available until December 31, 2024, with a minimum potential follow-up period of at least six months.
Exclusion Criteria
Subject…
Contacts
No contact information available.